On September 27, 2024, EMICRO Biomedicine made significant progress in the research and development of innovative drugs. The company successfully submitted the IND (New Drug Clinical Research Application) application materials for MS (Multiple Sclerosis) indication to the Drug Evaluation Center of the National Medical Products Administration.

  Multiple sclerosis, as a neurological disease that seriously affects the quality of life of patients, has always plagued human health. According to a survey by the world-renowned consulting firm Bezos, the global market size for the treatment of multiple sclerosis is expected to reach 174.5 billion yuan by 2024, and is projected to reach 242.7 billion yuan by 2029, with a compound annual growth rate of 5.48%. The domestic market size is expected to reach tens of billions of yuan. Faced with such a huge market, there are still many challenges and unmet needs in current treatment methods, and many pharmaceutical giants are also laying out research and development or clinical trials in this field.

  EMICRO Biomedicine Company has been committed to the research and development of innovative drugs, aiming to provide more effective treatment options for MS patients. The submission of this IND application is a reflection of the long-term efforts and extensive research work of the company's research team. The company's research personnel carried forward the spirit of teamwork, hard work, overcoming difficulties together, and daring to surpass, and deeply explored the pathogenesis and potential therapeutic targets of MS. Through advanced technical means and rigorous experimental design, they screened drug candidate compounds with good potential and completed preclinical research experiments.

  Preclinical animal experiments have shown that at the same dose, TM471-1 from EMICRO Biomedicine achieved the same MS efficacy as a similar product from an internationally renowned pharmaceutical company. However, TM471-1 has a significant advantage in brain BTK occupancy, indicating that the product will be more suitable for treating brain related diseases, which is a major benefit; Other data shows that TM471-1 is significantly superior to similar products on the market in multiple indicators such as heart and liver safety. TM471-1 from EMICRO Biomedicine is a promising product for the treatment of MS. EMICRO Medicine always adheres to the concept of "scientific, rigorous, innovative, and enterprising", and is committed to bringing more health benefits and life hope to patients at home and abroad.